MedWatch

Y-mabs CEO resigns with immediate effect

On Wednesday, Claus Møller has exited the executive management of Y-mabs, and company’s founder, Thomas Gad, steps in as interim CEO until a replacement has been found. A new chair has also been appointed.

Photo: Kelly Davidson Photography

Danish-American biotech firm Y-mabs is on the lookout for a new chief executive as the man in charge up to now, Claus Møller, has announced his departure from the role effective immediately, a company press release announced on Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs